The proteasome: a novel target for anticancer therapy

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Clinical and Translational Oncology

• Publication date

  2006-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/S12094-006-0176-8PMID 16760005
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells

  2006cited by this paper
• Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.

  2005cited by this paper
• Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.

  2005cited by this paper
• Activation of nuclear factor-κB in human prostate carcinogenesis and association to biochemical relapse

  2005cited by this paper
• PAD combination therapy (PS‐341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma

  2005cited by this paper
• Preclinical and clinical development of the proteasome inhibitor bortezomib in cancer treatment.

  2005cited by this paper
• Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell lymphoma.

  2005cited by this paper
• Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma

  2005cited by this paper
• Effects of bortezomib (PS-341) on NF-κB activation in peripheral blood mononuclear cells (PBMCs) of advanced non-small lung cancer (NSCLC) patients: A phase II/pharmacodynamic trial

  2004cited by this paper
• Phase II trial of bortezomib for patients with advanced renal cell carcinoma.

  2004cited by this paper
• NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis.

  2004cited by this paper
• The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts.

  2004cited by this paper
• The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor zenografts

  2004cited by this paper
• Phase I Study of Bortezomib in Refractory or Relapsed Acute Leukemias

  2004cited by this paper
• NF-κB activation in human breast cancer specimens and its role in cell proliferation and apoptosis

  2004cited by this paper
• Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.

  2004cited by this paper
• Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study.

  2004cited by this paper
• The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications.

  2003cited by this paper
• Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia.

  2002cited by this paper
• Bortezomib, a proteasome inhibitor, in cancer therapy: from concept to clinic

  2002cited by this paper
• A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies.

  2002cited by this paper
• NF-kappaB in cancer: from innocent bystander to major culprit.

  2002cited by this paper
• NF-κB in cancer: from innocent bystander to major culprit

  2002cited by this paper
• Proteasome inhibitors as new anticancer drugs

  2002cited by this paper
• Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.

  2002cited by this paper
• Proteasome inhibitors: from research tools to drug candidates.

  2001cited by this paper
• Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma.

  2001cited by this paper
• Crystal structure of the 20 S proteasome:TMC-95A complex: a non-covalent proteasome inhibitor.

  2001cited by this paper
• The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

  2001cited by this paper
• The apoptogenic response of human myeloid leukaemia cell lines and of normal and malignant haematopoietic progenitor cells to the proteasome inhibitor PSI

  2001cited by this paper
• The role of nuclear factor-?b in the biology and treatment of multiple myeloma

  2001cited by this paper
• Lactacystin Inhibits Cathepsin A Activity in Melanoma Cell Lines

  2001cited by this paper
• The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma.

  2001cited by this paper
• 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer

  2001cited by this paper
• Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells.

  2001cited by this paper
• Mechanisms underlying ubiquitination.

  2001cited by this paper
• Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition.

  2001cited by this paper
• Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome.

  2001cited by this paper
• Proteasome inhibitors induce caspase‐dependent apoptosis and accumulationof p21WAF1/Cip1 in human immatureleukemic cells

  2000cited by this paper
• Recognition of the polyubiquitin proteolytic signal

  2000cited by this paper
• Deregulation of the ubiquitin system and p53 proteolysis modify the apoptotic response in B-CLL lymphocytes.

  2000cited by this paper
• Subcellular localization of proteasomes and their regulatory complexes in mammalian cells.

  2000cited by this paper
• Response and determinants of sensitivity to paclitaxel in human non-small cell lung cancer tumors heterotransplanted in nude mice.

  2000cited by this paper
• Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition

  2000cited by this paper
• p27Kip1 accumulation by inhibition of proteasome function induces apoptosis in oral squamous cell carcinoma cells.

  2000cited by this paper
• Proteasome inhibitors induced caspase-dependent apoptosis and accumulation of p21WAF1/Cip1 in human immature leukemic cells.

  2000cited by this paper
• Inhibition of proteasome function induces programmed cell death in proliferating endothelial cells

  2000cited by this paper
• The proteasome controls the expression of a proliferation‐associated nuclear antigen Ki‐67

  2000cited by this paper
• The Proteasome, a Novel Protease Regulated by Multiple Mechanisms*

  1999cited by this paper
• Proteasome inhibitors: a novel class of potent and effective antitumor agents.

  1999cited by this paper
• Eponemycin exerts its antitumor effect through the inhibition of proteasome function.

  1999cited by this paper
• The proteasome: a macromolecular assembly designed for controlled proteolysis.

  1999cited by this paper
• Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB

  1999cited by this paper
• Increased sensitivity of CLL‐derived lymphocytes to apoptotic death activation by the proteasome‐specific inhibitor lactacystin

  1999cited by this paper
• The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis.

  1998cited by this paper
• A subcomplex of the proteasome regulatory particle required for ubiquitin-conjugate degradation and related to the COP9-signalosome and eIF3.

  1998cited by this paper
• Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor.

  1998cited by this paper
• The proteasome is involved in angiogenesis.

  1998cited by this paper
• Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids.

  1998cited by this paper
• Structure and assembly of the 20S proteasome

  1998cited by this paper
• The ubiquitin–proteasome pathway: on protein death and cell life

  1998cited by this paper
• Cleavage motifs of the yeast 20S proteasome beta subunits deduced from digests of enolase 1.

  1998cited by this paper
• Proteasome inhibitors and antigen presentation.

  1997cited by this paper
• Activation of NF-kappaB by antineoplastic agents. Role of protein kinase C.

  1997cited by this paper
• In vivo ubiquitination and proteasome-mediated degradation of p53(1).

  1996cited by this paper
• Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin

  1995cited by this paper
• Changes in expressions of proteasome and ubiquitin genes in human renal cancer cells.

  1991cited by this paper
• cDNA cloning and sequencing of component C9 of proteasomes from rat hepatoma cells

  1990cited by this paper
• Identity of the 19S 'prosome' particle with the large multifunctional protease complex of mammalian cells (the proteasome)

  1988cited by this paper

• Synthesis and evaluation of boron-containing heterocycles as drug candidates: Benzoxazaborinins as PARP inhibitors

  2026cites this paper
• Association between Parkinson’s Disease and Cancer: New Findings and Possible Mediators

  2024cites this paper
• Preparation of novel CaMoO4:Eu3+-MCM-41 nanocomposites and their applications and monitoring as drug release systems

  2021cites this paper
• Design and NMR conformational analysis in solution of β5i-selective inhibitors of immunoproteasome

  2020cites this paper
• Cancer risk in patients with Parkinson's disease in South Korea: A nationwide, population-based cohort study.

  2019cites this paper
• CLINICAL CHARACTERISTICS AND TREATMENT RESULTS OF PEDIATRIC RELAPSED/REFRACTORY NON-HODGKIN’S LYMPHOMAS

  2018cites this paper
• Preclinical drug screen reveals topotecan, actinomycin D, and volasertib as potential new therapeutic candidates for ETMR brain tumor patients

  2017cites this paper
• Détection précoce et quantification objective par mesures chronoampérometriques de l’atteinte neurologique périphérique chez des patients recevant une chimiothérapie neurotoxique

  2017cites this paper
• Pentacyclic triterpenoids: Discovery of new drugs with antitumour activity

  2017cites this paper
• Andrographolide from the herb Andrographis paniculata induces apoptosis on cultured human leukemic cells

  2017cites this paper
• Comparison of antiproliferative and apoptotic effects of a novel proteasome inhibitor MLN2238 with bortezomib on K562 chronic myeloid leukemia cells

  2016cites this paper
• High nuclear expression of proteasome activator complex subunit 1 predicts poor survival in soft tissue leiomyosarcomas

  2016cites this paper
• Caracterização da tolerância ao estresse oxidativo, capacidade de remoção de proteínas oxidadas e a expectativa de vida de linhagens da levedura S. cerevisiae com mutações sítio-específicas na subunidade α5 do proteassomo 20S: implicações na prevenção de agregação.

  2015cites this paper
• shRNA Depletion of cIAP1 Sensitizes Human Ovarian Cancer Cells to Anticancer Agent-Induced Apoptosis

  2015cites this paper
• Curcumin as a protector for normal cells during bortezomib therapy

  2015cites this paper
• Synthesis, Characterization and Radiolabeling of Bortezomib with 99mTC

  2015cites this paper
• Synergistic suppression of the PI3K inhibitor CAL-101 with bortezomib on mantle cell lymphoma growth

  2015cites this paper
• An Overview of Bortezomib-Induced Neurotoxicity

  2015cites this paper
• Cáncer de pulmón en el área sanitaria de Pontevedra: características clínicas, anatomopatológicas y factores pronósticos

  2014cites this paper
• Bortezomib Treatment Produces Nocifensive Behavior and Changes in the Expression of TRPV1, CGRP, and Substance P in the Rat DRG, Spinal Cord, and Sciatic Nerve

  2014cites this paper
• Molecular mechanisms of converting K562/DNR cellular drug-resistance by bortezomib.

  2014cites this paper
• Antineoplastic activity of strawberry (Fragaria×ananassa Duch.) crude extracts on B16-F10 melanoma cells.

  2014cites this paper
• Can Medical Herbs Stimulate Regeneration or Neuroprotection and Treat Neuropathic Pain in Chemotherapy-Induced Peripheral Neuropathy?

  2013cites this paper
• Proteases as Targets in Anticancer Therapy Using Their Inhibitors

  2013cites this paper
• FOXM1 (Forkhead box M1) in tumorigenesis: overexpression in human cancer, implication in tumorigenesis, oncogenic functions, tumor-suppressive properties, and target of anticancer therapy.

  2013cites this paper
• Dynamics of tumor progression and therapy response in Il-6 and Myc driven plasma cell malignancy

  2013cites this paper
• Neuropathy Secondary to Chemotherapy: A Real Issue for Cancer Survivors

  2012cites this paper
• The 26S proteasome complex: an attractive target for cancer therapy.

  2012cites this paper
• Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention.

  2012cites this paper
• Effect of inhibition of the Ubiquitin-Proteasome System and Hsp90 on growth and survival of Rhabdomyosarcoma cells in vitro

  2012cites this paper
• Naltrindole Inhibits Human Multiple Myeloma Cell Proliferation In Vitro and in a Murine Xenograft Model In Vivo

  2012cites this paper
• The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence-dependent way with chemotherapeutic agents in mantle cell lymphoma

  2012cites this paper
• Bowman-Birk inhibitors, proteasome peptidase activities and colorectal pre neoplasias induced by 1,2-dimethylhydrazine in Swiss mice.

  2012cites this paper
• Heterozygosity for the proteasomal Psmc1 ATPase is insufficient to cause neuropathology in mouse brain, but causes cell cycle defects in mouse embryonic fibroblasts.

  2012cites this paper
• Chemosensitivity of conjunctival melanoma cell lines to target-specific chemotherapeutic agents

  2012cites this paper
• Chemotherapy-induced peripheral neurotoxicity (CIPN): an update.

  2012cites this paper
• Chemotherapy-induced peripheral neuropathy in pediatric cancer patients.

  2012cites this paper
• Understanding the link between cancer and neurodegeneration

  2012cites this paper
• Distinct regulatory mechanisms of eukaryotic transcriptional activation by SAGA and TFIID.

  2011cites this paper
• Análise do perfil de expressão gênica de linhagens epiteliais mamárias humanas submetidas ao tratamento com rapamicina associada à doxorrubicina

  2011cites this paper
• Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.

  2011cites this paper
• The screening for novel proteasome inhibitors as a treatment of cancer using IncuCyte FLR and fluorometric microculture cytotoxicity assay.

  2011cites this paper
• Proteomic analysis of anti-tumor effects by tetrandrine treatment in HepG2 cells.

  2010cites this paper
• Recent advances in the treatment of mantle cell lymphoma: a post-ASH 2009 discussion.

  2010cites this paper
• The prognostic potential of the epidermal growth factor receptor and nuclear factor kappa B pathways and associated therapeutic strategies in patients with squamous cell carcinoma of the head and neck

  2010cites this paper
• Clinical Detection and Treatment of Thyroid Diseases

  2010cites this paper
• Targets for cancer therapy in childhood sarcomas.

  2010cites this paper
• Evaluation of the anticancer potential of plants used as traditional medicines by Aboriginal people

  2010cites this paper
• The Role of the immunoproteasome in Inflammatory Bowel Disease

  2010cites this paper
• Nature as Source of Medicines; Novel Drugs from Nature; Screening for Antitumor Activity

  2010cites this paper
• Drug-related cardiotoxicity for the treatment of haematological malignancies in elderly.

  2010cites this paper
• Fetal bovine serum requirement for pyrrolidine dithiocarbamate-induced apoptotic cell death of MCF-7 breast tumor cells.

  2010cites this paper
• Chemotherapy-induced peripheral neurotoxicity

  2010cites this paper
• Programmed cell death 4 (PDCD4) mediates the sensitivity of gastric cancer cells to TRAIL-induced apoptosis by down-regulation of FLIP expression.

  2010cites this paper
• Parkinson’s disease and cancer risk: a systematic review and meta-analysis

  2010cites this paper
• p53‐induced RING‐H2 protein, a novel marker for poor survival in hepatocellular carcinoma after hepatic resection

  2009cites this paper
• Review Article Overcoming cancer therapy resistance by targeting inhibitors of apoptosis proteins and nuclear factor- kappa B

  2009cites this paper
• Proteasome inhibition modulates kinase activation in neural cells: Relevence to ubiquitination, ribosomes, and survival

  2009cites this paper
• Overcoming cancer therapy resistance by targeting inhibitors of apoptosis proteins and nuclear factor-kappa B.

  2009cites this paper
• Bronchial Asthma, Chronic Obstructive Pulmonary Disease and NF-κB

  2009cites this paper
• Role of oxidative stress and intracellular glutathione in the sensitivity to apoptosis induced by proteasome inhibitor in thyroid cancer cells

  2009cites this paper
• PSMB7 is associated with anthracycline resistance and is a prognostic biomarker in breast cancer

  2009cites this paper
• The Nuclear Factor-κB Pathway Regulates Cytochrome P450 3A4 Protein Stability

  2008cites this paper
• Drug-induced apoptosis in yeast.

  2008cites this paper
• Diverse Regulatory Mechanisms of Eukaryotic Transcriptional Activation by the Proteasome Complex

  2008cites this paper
• Proteasome Inhibition: Potential for Sensitization of Immune Effector Mechanisms in Cancer

  2008cites this paper
• Multitargeted therapy of cancer by green tea polyphenols.

  2008cites this paper
• The Nuclear Factor-B Pathway Regulates Cytochrome P 450 3 A 4 Protein Stability

  2008cites this paper
• Antitumor Activity of Bortezomib Alone and in Combination with Trail in Human Acute Myeloid Leukemia

  2008cites this paper
• Evidence for the Mode of Action of the Highly Cytotoxic Streptomyces Polyketide Kendomycin

  2007cites this paper
• Lung cancer: Future directions

  2007cites this paper
• Characterization of the pro-apoptotic function of eIF5A in human cancer cell lines

  2007cites this paper
• Proteasome inhibitors synergize with tumor necrosis factor-related apoptosis-induced ligand to induce anaplastic thyroid carcinoma cell death.

  2007cites this paper
• LMP2-specific inhibitors: chemical genetic tools for proteasome biology.

  2007cites this paper
• Prospective case–control study of nonfatal cancer preceding the diagnosis of parkinson’s disease

  2007cites this paper